Received Jul 21, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | UNK | LA |
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | — |
The patient never went back for the second dose of the series; shingles on the back of his left leg hamstring area; This non-serious case was reported by a consumer via call center representative and described the occurrence of shingles in an elderly male patient who received Herpes zoster (Shingrix) for prophylaxis. Co-suspect products included Herpes zoster (Shingrix) for prophylaxis. In AUG-2024, the patient received the 1st dose of Shingrix (left arm). On an unknown date, the patient received the 2nd dose of Shingrix. In AUG-2024, not applicable after receiving Shingrix and an unknown time after receiving Shingrix, the patient experienced incomplete course of vaccination (Verbatim: The patient never went back for the second dose of the series). In SEP-2024, the patient experienced shingles (Verbatim: shingles on the back of his left leg hamstring area). In OCT-2024, the outcome of the shingles was resolved (duration 1 month). The outcome of the incomplete course of vaccination was not applicable. It was unknown if the reporter considered the shingles to be related to Shingrix. It was unknown if the company considered the shingles to be related to Shingrix. Additional Information: GSK Receipt Date: 15-JUL-2025 The patient received his first dose of Shingrix in August of 2024 left arm. One month later he developed shingles on the back of his left leg hamstring area. The shingles resolved one month after getting the rash. The patient never went back for the second dose of the series which led to incomplete course of vaccination.